Advertisement

Safety Pharmacology of Herbal Products

  • Gert Laekeman
Chapter

Abstract

This chapter aims at a comprehensive review on safety pharmacology. Foxglove and the discovery of acetylsalicylic acid are given as historical examples emerging from benefit-risk balance. Before going to practical examples of in vitro research, a theoretical approach is given to competitive and non-competitive antagonism. Results of experimental work are presented in order to show how early toxic activity can be detected and can even be related to mechanisms of action (e.g., the indole alkaloids of Pterotaberna inconspicua and the sesquiterpene lactone vernolepin from Vernonia amygdalina). If substances can be detected as responsible agents for a biological activity of complex mixtures, the safety approach can be simplified (e.g., eugenol in powder of Myristica fragrans). Pharmacokinetic considerations are important when taking into consideration safety and therapeutic issues of red yeast rice. A pharmacokinetic schedule is given and illustrated with herbal examples. Finally, a framework of questions is proposed to cover quality as well as pre-clinical and clinical safety.

Keywords

Pharmacology Safety History Checklist Pharmacokinetics Pharmacodynamics 

References

  1. Arunlakshana O, Schild M (1959) Some quantitative uses of drugs antagonists. Br J Pharmacol 14:48–58Google Scholar
  2. Bakana P, Laekeman GM, Totte J, Herman AG, Vlietinck AJ (1985) Stereochemical considerations in relation to the pharmacological activity of Pterotaberna alkaloids. J Nat Prod 48:766–771CrossRefPubMedGoogle Scholar
  3. Bennett A, Stamford IF, Tavares IA et al (1988) The biological activity of eugenol, a major constituent of nutmeg (Myristica fragrans): studies on prostaglandins, the intestines and other tissues. Phytother Res 2:124–130Google Scholar
  4. Booker A, Suter A, Krnjic A et al (2014) A phytochemical comparison of saw palmetto products using gas chromatography and 1H nuclear magnetic resonance spectroscopy metabolomic profiling. J Pharm Pharmacogn 66:811–822Google Scholar
  5. Born GVR (1962) Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 194:927–929CrossRefPubMedGoogle Scholar
  6. Breckenridge A (2006) William Withering’s legacy – for the good of the patient. Clin Med 6:393–397CrossRefGoogle Scholar
  7. Brownlee G, Johnson ES (1965) The release of acetylcholine from the isolated ileum of the guinea-pig induced by 5-hydroxytryptamine and dimethylphenylpiperazine. Br J Pharmacol 24: 689–700.Google Scholar
  8. Chaggar PS, Shaw SM, Williams SG (2015) Is foxglove effective in heart failure? Cardiovasc Ther. doi: 10.1111/1755-5922 [Epub ahead of print]PubMedGoogle Scholar
  9. Chan BS, Buckley NA (2014) Digoxin-specific antibody fragments in the treatment of digoxin toxicity. Clin Toxicol 52:824–836CrossRefGoogle Scholar
  10. Crawford N (1976) Platelete microfilaments and microtubules. In: Gordon JL (Ed) Platelets in biology and pathology. North-Holland Publishing Company, Amsterdam pp. 121–157.Google Scholar
  11. Day M, Vane JR (1963) An analysis of direct and indirect actions of drugs on the isolated guinea-pig ileum. Br J Pharmacol Chemother 20:150–170CrossRefPubMedPubMedCentralGoogle Scholar
  12. de Combarieu E, Martinelli EM, Pace R, Sardone N (2015) Metabolomics study of Saw palmetto extracts based on 1H NMR spectroscopy. Fitoterapia 102:56–60CrossRefPubMedGoogle Scholar
  13. De Monte C, Carradori S, Granese A, Di Pierro GB, Leonardo C, De Nunzio C (2014) Modern extraction techniques and their impact on the pharmacological profile of Serenoa repens extracts for the treatment of lower urinary tract symptoms. BMC Urol 14:63–74CrossRefPubMedPubMedCentralGoogle Scholar
  14. De Witte P, Lemli L (1990) The metabolism of anthranoid laxatives. Hepatogastroenterology 37:601–605PubMedGoogle Scholar
  15. De Witte P, Demeyer K, Delmulle L et al (2008) Pharmacokinetics. In: Delmulle L, Demeyer K (eds) Anthraquinones containing plants reconsidered. Standaard Uitgeverij, Antwerpen, pp 99–107Google Scholar
  16. Dong B, Li H, Singh AB, Cao A, Liu J (2015) Inhibition of PCSK9 transcription by berberine involves down regulation of hepatic HNF1-alpha protein expression through the ubiquitin-proteasome pathway. J Biol Chem 290:4047–4058CrossRefPubMedGoogle Scholar
  17. EMA (European Medicines Agency) (2012) Recommendation to marketing authorisation holders, highlighting the need to ensure compliance with 3Rs methods described in the European Pharmacopoeia. Committee for Medicinal Products for Human Use (CHMP) and Committee for Medicinal Products for Veterinary Use (CVMP), EMAGoogle Scholar
  18. EMA (European Medicines Agency) (2014) Public statement on the use of herbal medicinal products containing estragole. Committee on Herbal Medicinal Products, EMAGoogle Scholar
  19. Fong CW (2014) Statins in therapy: understanding their hydrophilicity, lipophilicity, binding to 3-hydroxy-3-methylglutaryl-CoA reductase, ability to cross the blood brain barrier and metabolic stability based on electrostatic molecular orbital studies. Eur J Med Chem 85:661–674CrossRefPubMedGoogle Scholar
  20. Frohne D (1970) Untersuchungen zur Frage der harndesinfizierenden Wirkungen von Bärentraubenblatt-Extrakten. Planta Med 18:1–25CrossRefPubMedGoogle Scholar
  21. Grigoras N, Purdel C (2014) Assessment report on Camellia sinensis (L.) Kuntze, non fermentatum folium. European Medicines Agency. http://www.ema.europa.eu/ema/
  22. Habib FK, Wyllie MG (2004) Not all brands are created equal: a comparison of selected components of different brands of Serenoa repens.. Prostate Cancer Prostatic Dis 7:195–200CrossRefPubMedGoogle Scholar
  23. Hauptmann PJ, Kelly RA (1999) Digitalis. Circulation 99: 1265–1270.Google Scholar
  24. Heroutová M (2012) Assessment report on Arctostaphylos uva-ursi (L.) Spreng., folium. EMA. http://www.ema.europa.eu/ema/
  25. ICH (2001) Guidance for Industry: S7A safety pharmacology studies for human pharmaceuticals. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER)Google Scholar
  26. Janssens J, Laekeman GM, Pieters LAC, Totte J, Herman AG, Vlietinck AJ (1990) Nutmeg oil: identification and quantification of its most active constituents as inhibitors of platelet aggregation. J Ethnopharmacol 29:179–188CrossRefPubMedGoogle Scholar
  27. Jeffreys D (2005) The remarkable story of a wonder drug Aspirin. Bloomsbury, London, pp 5–74Google Scholar
  28. Kyle R, Shampe M (1974). Discoverers of quinine. JAMA. 229 (4): 462.Google Scholar
  29. Laekeman G (1980) Pharmacological study of the Schulz-Dale reaction. University of Antwerp, PhD thesisGoogle Scholar
  30. Laekeman G (1988) Phytopharmacological study of vernolepin and eugenol. University of Antwerp, PhD aggregation thesisGoogle Scholar
  31. Laekeman GM, Mertens J, Totte J, Bult H, Vlietinck AJ, Herman AG (1983) Isolation and pharmacological characterization of vernolepin. J Nat Prod 46:161–169CrossRefPubMedGoogle Scholar
  32. Laekeman GM, De Clerck F, Vlietinck AJ, Herman AG (1985) Vernolepin: an antiplatelet compound of natural origin. Naunyn Schmiedeberg’s Arch Pharmacol 331:108–113CrossRefGoogle Scholar
  33. Lanoxin (2015) Summary of Product Characteristics last update June 2015Google Scholar
  34. Löwig C, Weidmann S (n.d.) Beiträge zur organischen Chemie (Contributions to organic chemistry); “III. Untersuchungen mit dem destillierten Wasser der Blüthen von Spiraea Ulmaria” (III. Investigations of the water distilled from the blossoms of Spiraea ulmaria). Annalen der Physik und Chemie 46:45–91; 57–83Google Scholar
  35. Lu Z, Kou W, Du B et al (2008) Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction. Am J Cardiol 101:1689–1693CrossRefPubMedGoogle Scholar
  36. Mazzanti G, Di Sotto A, Vitalone A (2015) Hepatotoxicity of green tea: an update. Arch Toxicol 89:1175–1191CrossRefPubMedGoogle Scholar
  37. Nijenhuis CM, ter Horst PGJ, de Jong-van den Berg LTW, Wilffert B (2011) Disturbed development of the enteric nervous system after in utero exposure of selective serotonin re-uptake inhibitors and tricyclic antidepressants. Part 1: literature review. Br J Clin Pharmacol 73:16–26CrossRefGoogle Scholar
  38. Ouyang AJ, Lv YN, Zhong HL, Wen JH, Wei XH, Peng HW, Zhou J, Liu LL (2015) Meta-analysis of digoxin use and risk of mortality in patients with atrial fibrillation. Am J Cardiol 115(7):901–916CrossRefPubMedGoogle Scholar
  39. Perry LM (1980) Medicinal plants of East and Southeast Asia: attributed properties and uses. MIT Press, Cambridge, MA, pp 141–142, 153 and 227–228Google Scholar
  40. Pugsley MK, Authier S, Curtis MJ (2008) Review: frontiers in pharmacology. Principles of safety pharmacology. Br J Pharmacol 154:1382–1399CrossRefPubMedPubMedCentralGoogle Scholar
  41. Rasheed A, Laekeman G, Totte J, Vlietinck AJ, Herman AG (1984) Eugenol and prostaglandin biosynthesis. NEJM 310:50–51PubMedGoogle Scholar
  42. Roquebert J, Dufour P, Canellas J (1971) Action of some morphine analgesics on the effects of coaxial electric stimulation of the isolated guinea-pig ileum. C R Seances Soc Biol Fil 165:577–580Google Scholar
  43. Scaglione F, Lucini V, Pannacci M, Caronno A, Leone C (2008) Comparison of the potency of different brands of Serenoa Repens extract on 5alpha-reductase Types I and II in prostatic co-cultured epithelial and fibroblast cells. Pharmacology 82:270–275CrossRefPubMedGoogle Scholar
  44. Scaglione F, Lucini V, Pannacci M, Dugnani S, Leone C (2012) Comparison of the potency of 10 different brands of Serenoa repens.. Eur Rev Med Pharmacol Sci 16:569–574PubMedGoogle Scholar
  45. Schmitz, R (1985). Friedrich Wilhelm Sertürner and the discovery of morphine”. Pharmacy in history. 27 (2): 61–74.Google Scholar
  46. Tayebati SK, Piergentili A, Natale D, Amenta F (1999) Evaluation of an agonist index: affinity ratio for compounds active on muscarinic cholinergic M2 receptors. J Auton Pharmacol 19:77–84CrossRefPubMedGoogle Scholar
  47. Van Nueten JM, Janssens AJ, Fontaine J (1976) Unexpected reversal effects of naloxone on the guinea pig ileum. Life Sci 18:803–809CrossRefPubMedGoogle Scholar
  48. Van Rossum JM (1963) Cumulative dose-response curves II. Technique for the making of dose-response curves in isolated organs and the evaluation of drug parameters. Arch Int Pharmacodyn 143:299–330Google Scholar
  49. Vane J (1971) Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 231:232–235CrossRefPubMedGoogle Scholar
  50. Vial T, Bernard G, Lewden B, Dumortier J, Descotes J (2003) Hépatite aiguë imputable à l’Exolise® (Camellia sinensis). Gastroenterol Clin Biol 27(12):1166PubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2017

Authors and Affiliations

  1. 1.Clinical Pharmacology and PharmacotherapyFaculty of Pharmaceutical Sciences, KU LeuvenLeuvenBelgium

Personalised recommendations